Answer
Breastfeeding must be discontinued during Tukysa (tucatinib) treatment and may resume one week after treatment, because excretion into human milk is unknown and a risk to newborns or infants cannot be excluded.
Sources for this answer
- TUKYSA 50 mg film-coated tabletPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 5Document updated
Sources checked